CAP [mdash] advancing the evaluation of preclinical Alzheimer disease treatments, Nat Rev Neurol. 2015 Sep 29, Reiman EM1, Langbaum JB1, Tariot PN1, Lopera F2, Bateman RJ3, Morris JC3, Sperling RA4, Aisen PS5, Roses AD6, Welsh-Bohmer KA6, Carrillo MC7,Weninger S8.
- 1Banner Alzheimer‘s Institute, 901 E. Willetta Street, Phoenix, AZ 85006, USA.
- 2Grupo de Neurosciencias, Universidad de Antioquia, Calle 62 #52-59, Medellin, Colombia.
- 3Department of Neurology, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.
- 4Department of Neurology, Brigham and Women’s Hospital, 221 Longwood Avenue, Boston, MA 02115, USA.
- 5University of Southern California Alzheimer‘s Therapeutic Research Institute, 10182 Telesis Court, San Diego, CA 92121, USA.
- 6Joseph and Kathleen Bryan Alzheimer‘s Disease Research Center, Department of Neurology, Duke University Medical Center, 2200 West Main Street, Durham, NC 27705, USA.
- 7Alzheimer‘s Association, Medical &Scientific Relations Division, 225 North Michigan Avenue, Chicago, IL 60601, USA.
- 8Fidelity Biosciences Research Initiative, One Main Street, Cambridge, MA 02142, USA.
If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies inpreclinical AD treatment. We describe the Collaboration for Alzheimer‘s Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.